Uncategorized
Aldeyra submits IND application for phase 2 testing of uveitis treatment
Aldeyra Therapeutics has submitted an investigational new drug application to the U.S. Food and Drug Administration to conduct phase 2 clinical testing of its product, NS2, for the treatment of noninfectious anterior uveitis.“The submission of an IND for NS2 in the treatment of noninfectious anterior uveitis is a major milestone for Aldeyra and is another step forward in the execution of our development strategy,” Todd C. Brady, MD, PhD, president and CEO of Aldeyra, said in a company press release. “NS2 has the potential to reduce or eliminate the use (Read more...)